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Abstract
Background The 52-week safety and efficacy of adali-
mumab in Japanese patients with moderately to severely
active ulcerative colitis were demonstrated in a placebo-
controlled phase 2/3 trial. Data from patients who enrolled
in the open-label extension study are presented.
Methods Remission and response per the full Mayo score
(FMS) and the partial Mayo score (PMS), remission per the
Inflammatory Bowel Disease Questionnaire (IBDQ) score,
corticosteroid-free remission, and mucosal healing were
assessed up to week 196 (week 208 for remission/response
per PMS) of adalimumab treatment in patients who
received one or more doses of adalimumab with use of a
hybrid nonresponder imputation (hNRI) method. Nonre-
sponder imputation was used for missing data up to the
latest possible follow-up date for each patient, followed by
observed case. Adalimumab trough concentrations were
reported from week 52 to week 196 of treatment. Treat-
ment-emergent adverse events were reported for all adali-
mumab-treated patients.
Results Two hundred sixty-six patients received adali-
mumab. At week 196 of treatment, remission and response
rates per FMS, remission and response rates per PMS,
remission rate per IBDQ score, mucosal healing rate, and
corticosteroid-free remission rate were 19.2%, 32.2%,
22.5%, 32.5%, 33.1%, 30.5% (hNRI), and 40.5% (17/42; as
observed), respectively. Serum adalimumab concentrations
remained constant in patients receiving 40 mg every other
week but increased in patients who underwent dose esca-
lation. The safety profile was consistent with that in the
52-week study.
Conclusions The efficacy of adalimumab in Japanese
patients with moderately to severely active ulcerative col-
itis was maintained for up to 4 years of treatment. No new
safety signals were observed.
Keywords Clinical remission  Tumor necrosis factor
Introduction
Ulcerative colitis is an inflammatory bowel disease in
which inflammation of the colonic mucosal surface is
characterized by bloody diarrhea, urgency, tenesmus,
abdominal pain, and fever in some cases [1]. Patients
experience periods of relapse and remission, although
many patients have chronically active disease, with sub-
stantial impact on quality of life [1–4].
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The incidence and prevalence of inflammatory bowel
diseases such as ulcerative colitis and Crohn’s disease are
lower in Asian countries than in the West but are rapidly
increasing, especially in East Asia and Japan [5–7]. The
prefecture prevalence of ulcerative colitis and Crohn’s
disease in Japan in 2011, when this study began, ranged
from 64.8 to 117.4 per 100 000 person-years [8]. Global
estimates of ulcerative colitis prevalence range from 4.9 to
505 in Europe, from 37.5 to 248.6 in North America, and
from 4.9 to 168.3 in Asia and the Middle East [9].
Elevated levels of tumor necrosis factor a (TNFa) in the
serum, stools, and mucosa of patients with ulcerative colitis
suggest a prominent role for this inflammatory cytokine in
the pathogenesis of ulcerative colitis, a premise supported
by the effectiveness of anti-TNFa treatments [1, 10–12].
The 52-week efficacy and safety of adalimumab, a fully
human monoclonal antibody that targets TNFa, in Western
patients with moderately to severely active, treatment-re-
fractory ulcerative colitis were demonstrated in the phase 3
studies ULTRA 1 and ULTRA 2 [13–16]. A long-term
open-label extension study that enrolled patients from both
of these studies (ULTRA 3) demonstrated that the efficacy
and safety of adalimumab are maintained for up to
208 weeks of treatment [17].
The safety and efficacy of adalimumab in Japanese
patients with moderately to severely active ulcerative col-
itis were demonstrated in a 52-week phase 2/3 study [18].
In this report, we present the results of up to 208 weeks of
adalimumab treatment in all patients who received one or
more doses of adalimumab in the phase 2/3 study and an
open-label extension study, studies conducted to evaluate
the long-term efficacy and safety of adalimumab in Japa-




Detailed information about the design of the 52-week
phase 2/3 study and patient disposition in that study have
been published [18]. Briefly, the 52-week phase 2/3 study
was a randomized, double-blind, placebo-controlled trial
evaluating the efficacy, safety, and pharmacokinetics of
adalimumab as induction (weeks 0–8) and maintenance
(from week 8) therapy in Japanese patients aged 15 years
or older who had biopsy-confirmed, moderately to severely
active ulcerative colitis (i.e., Mayo score 6–12; endoscopy
subscore 2 or greater) despite concurrent treatment with
oral corticosteroids or immunomodulators (or both) [18].
Patients (N = 274) were randomized 1:1:1 to receive
160 mg adalimumab at week 0, 80 mg adalimumab at
week 2, and 40 mg adalimumab every other week from
week 4 (160/80 arm); 80 mg adalimumab at week 0, 40 mg
adalimumab at week 2, and 40 mg adalimumab every other
week from week 4 (80/40 arm); or placebo. Patients in any
study arm who had an inadequate response at or after week
8 could move to an open-label rescue arm [18]. Rescue
treatment consisted of 4 weeks of blinded adalimumab
therapy (160 mg initially and 80 mg 2 weeks later for
patients in the placebo arm, or 40 mg initially and 2 weeks
later for patients in either adalimumab arm) followed by
open-label adalimumab 40 mg therapy every other week,
with the possibility of escalation to 80 mg every other
week in the case of inadequate response or disease flare.
Patients who received placebo or adalimumab (in either
the double-blind phase or the rescue arm) and completed
the 52-week study received open-label adalimumab 40 mg
therapy every other week from week 52 until approval of
adalimumab therapy for ulcerative colitis by Japanese
authorities during an open-label extension study. On entry
into the extension study, patients whose treatment was
escalated to 80 mg adalimumab every other week by week
52 continued with the same dose. Self-injection of the
study drug was allowed after week 52, as appropriate.
During the open-label extension study, escalation of the
adalimumab dose to 80 mg every other week was allowed
at or after week 60 from the lead-in study baseline for
patients experiencing inadequate response or disease flare.
Inadequate response was defined as a partial Mayo score
(PMS; i.e., the Mayo score without the endoscopy sub-
score) greater than or equal to the baseline PMS on two
consecutive visits at least 14 days apart for patients with a
baseline PMS of 3–7, or PMS of 7 or greater on two
consecutive visits at least 14 days apart for patients with a
baseline PMS of 8 or 9. Disease flare was defined as a PMS
difference of 3 or greater compared with PMS at week 52
or at the last evaluation before the disease flare on two
consecutive visits at least 14 days apart. Patients who
continued to have inadequate response or disease flare
while receiving 80 mg adalimumab every other week were
to be withdrawn from the study.
Efficacy assessments
The baseline for this analysis was defined as the day of the
first adalimumab dose for each patient. Long-term efficacy
was analyzed from the first dose of adalimumab up to
196 weeks of treatment in all patients who received one or
more doses of adalimumab in the phase 2/3 study or the
open-label extension study (the ‘‘any ADA’’ set). This
analysis set included patients who were randomized to
receive placebo but who received adalimumab as rescue
therapy during the phase 2/3 lead-in study or during the
open-label extension study. Efficacy end points were
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remission defined by the full Mayo score (FMS; 2 points or
less with no individual subscore greater than 1 point),
remission defined by PMS (2 points or less with no indi-
vidual subscore greater than 1 point), and remission defined
by the Inflammatory Bowel Disease Questionnaire (IBDQ;
score 170 points or greater); change from the baseline in
the IBDQ, response by FMS [decrease in FMS of 3 points
or more and 30% or more from the baseline plus a decrease
in the rectal bleeding subscore (RBS) of 1 point or more or
an absolute RBS of 0 or 1], and response by PMS (decrease
in PMS of 2 points or more and 30% or more from the
baseline plus a decrease in RBS of 1 point or more or an
absolute RBS of 0 or 1); and mucosal healing (endoscopy
subscore 1 or less). The change from the baseline in the
mean physical and mental summary scores of the 36-item
short-form quality-of-life assessment (SF-36) was also
reported for the any ADA set. Discontinuation of corti-
costeroid therapy and corticosteroid-free remission (Mayo
score 2 or less with no individual subscore greater than 1
and discontinuation of corticosteroid therapy) were asses-
sed in patients who received corticosteroids at the baseline
of the lead-in phase 2/3 study (n = 175). An additional
analysis was performed on the any ADA set for remission
and response by FMS, remission and response by PMS, and
mucosal healing, whereby patients were imputed as non-
responders at the time of escalation to dosing at 80 mg
every other week. These data are reported as ‘‘no dose
escalation.’’
During the double-blind study, PMS was evaluated at
weeks 2, 4, 6, and 8, and monthly thereafter, and FMS was
evaluated at weeks 8, 32, and 52 [18]. During the open-
label extension study (i.e., after week 52), PMS was
evaluated every 12 weeks and at the completion or early
termination visit. Because endoscopy was performed every
48 weeks during the open-label extension study, FMS was
also evaluated every 48 weeks and at the completion or
early termination visit. Stool frequency subscore and RBS
were evaluated on the basis of patients’ diary entries, with
use of the worst diary entry from the 3 days before each
study visit for each patient-reported subscore. IBDQ and
SF-36 scores were evaluated every 24 weeks after week 52
and at the completion or early termination visit.
Pharmacokinetics and anti-adalimumab antibodies
Methods for the assessment of pharmacokinetics and anti-
adalimumab antibodies (AAAs) have been described [18].
In the open-label extension study, blood samples were
obtained for evaluation of serum adalimumab and AAAs
every 24 weeks after week 52, at the completion or early
termination visit, and at the 28-day follow-up visit. Sam-
ples were assessed by use of a validated enzyme-linked
immunosorbent assay based on a double-antigen technique.
The lower limit of quantitation for adalimumab was
3.13 ng/mL in diluted serum and 31.3 ng/mL in undiluted
serum. AAA was measured in serum samples in which the
adalimumab concentration was less than 20 ng/mL. The
lower limit of quantitation for AAA was 1.0 ng/mL in
diluted serum and 10 ng/mL in undiluted serum. Trough
serum concentrations over time from week 52 of the lead-
in study were summarized by dose-escalation status (i.e.,
continuing with 40 mg every other week versus escalation
to 80 mg every other week) and by AAA status for patients
randomized to receive adalimumab in the lead-in study and
who entered the open-label extension study.
Safety assessments
Adverse events and changes in laboratory variables and
vital signs were monitored throughout the study. During
the open-label extension study (after week 52), vital signs
were recorded and physical examination and laboratory
tests performed every 12 weeks; chest X-rays (as part of
tuberculosis screening and pregnancy testing) were
obtained every 24 weeks.
Statistical methods
Because patients in the any ADA cohort received their first
adalimumab dose at different times and therefore had
various durations of follow-up, the categorical efficacy end
points were analyzed by use of a hybrid nonresponder
imputation (hNRI) method. This was used because use of
standard nonresponder imputation would not have accu-
rately reflected the long-term efficacy of adalimumab in
patients with ulcerative colitis who discontinued partici-
pation in the study per protocol because of the approval of
adalimumab in Japan and not for clinical reasons. The
latest possible visit for an individual patient in the study
was based on the time from his/her first dose of adali-
mumab to the date of the approval of adalimumab for
treatment of ulcerative colitis in Japan on June 14, 2014;
consequently, the follow-up time was not the same in all
patients. In the hNRI analysis, a patient was considered not
to have efficacy if he/she discontinued participation in the
study or had missing data up to his/her latest possible visit.
Afterward, an observed-case analysis was applied (i.e.,
patients were not included in the nonresponder imputation
analysis at visit weeks beyond their latest possible visit).
This resulted in a decrease of the denominator for binary
end point calculations in the any ADA cohort after week
112.
Patients whose dose was escalated to 80 mg adali-
mumab every other week were not imputed as nonre-
sponders for efficacy unless specified otherwise (‘‘no dose
escalation’’). The change from the baseline in the physical
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and mental components of SF-36, the change from the
baseline in the IBDQ score, discontinuation of corticos-
teroid therapy, and corticosteroid-free remission were
reported as observed. For the pharmacokinetic analysis,
adalimumab concentration is summarized by treatment
group at each time point by use of descriptive statistics,
including the number of patients; the number of nonmiss-
ing observations; mean, median, and standard deviation;
coefficient of variation; and minimum, maximum, and
geometric mean. Serum AAA concentrations are listed by
treatment group at each collection time.
Results
Patient disposition and baseline characteristics
The disposition of the patients in the double-blind and
extension periods of the study is shown in Fig. 1. Two
hundred sixty-six patients received adalimumab (any ADA
set) either during the double-blind period (177 patients
randomized to receive adalimumab and 63 randomized to
receive placebo who received adalimumab in the rescue
arm) or the open-label extension period, in which 26
patients received adalimumab for the first time. Of the 191
patients who completed the lead-in study to week 52, 190
entered the open-label extension study (91 patients who
had completed the double-blind therapy and 99 patients
who had completed the open-label adalimumab therapy);
65 patients discontinued participation during the open-label
extension study, most commonly because of lack of effi-
cacy (27 patients). A total of 42.1% of patients (112/266) in
the any ADA set received adalimumab at 80 mg every
other week during the lead-in study or the open-label
extension study. Of the 266 patients in the any ADA set,
119 patients (44.7%) completed the study.
The demographics and patient characteristics in the any
ADA set at the time of enrollment in the lead-in study are
shown in Table 1. Most patients were male (175/266; 65.8%),
the mean age was 42.6 years (range 15–74 years), and 64.3%
of patients had pancolitis. The mean duration of ulcerative
colitis was 8.1 years (range 0.4–37.8 years), and the mean
FMS and PMS were 8.5 and 6.1, respectively, consistent with
a diagnosis of moderate-to-severe ulcerative colitis.
Remission, response, and mucosal healing over time
Remission (per FMS), response (per FMS), and mucosal
healing were achieved early and were sustained throughout
the study (Fig. 2). Data are presented from the first adali-
mumab dose to week 196 for the end points based on FMS
or PMS. At week 196 of adalimumab treatment, hNRI




analysis in the any ADA set gave rates of remission and
response per FMS of 19.2% (34/177) and 32.2% (57/177)
respectively (Fig. 2a, b); the rates of remission and
response per PMS were 22.5% (27/120) and 32.5% (39/
120) respectively (Fig. S1). When patients were imputed as
nonresponders at the time of moving to 80 mg every other
week, the rates of response at week 196 of treatment per
FMS and PMS by hNRI analysis were 23.2% (41/177) and
22.5% (27/120), respectively (Figs. 2b, S1b; no dose
escalation). In addition, PMS data were collected up to
week 208; PMS remission and response rates were 26.5%
(22/83) and 34.9% (29/83), respectively, by hNRI analysis
in the any ADA set, and when patients whose treatment
was escalated to 80 mg every other week were imputed as
nonresponders, the PMS response rate was 24.1% (20/83)
by hNRI analysis (data not shown).
The proportion of patients with mucosal healing
remained stable from week 8 through week 196 of treat-
ment (30.8–30.5%) (Fig. 2c).
Corticosteroid-free remission
In the any ADA set, 65.8% of patients (175/266) used
corticosteroids at the lead-in study baseline. From week
32 through week 196 of adalimumab treatment, the
proportion of patients who discontinued corticosteroid
therapy increased from 32.8% (42/128) to 69.0% (29/42;
observed analysis) (Fig. 3). The corticosteroid-free
remission rate in patients in the any ADA set who used
corticosteroids at the lead-in study baseline increased
from 10.2% (13/128 patients) at week 32 to 38.0% (35/
92) at week 100 and remained stable through week 196
of adalimumab treatment [40.5% (17/42); observed
analysis].
Health-related quality of life
Remission rates by the IBDQ score (IBDQ score 170
points or greater) remained stable from week 8 through
week 196 of adalimumab treatment (Fig. 4). The mean
change from the baseline in the SF-36 physical and
mental component scores increased from week 8 through
week 196 of adalimumab treatment (Fig. S2). Similarly,
the mean change from the baseline in the IBDQ score
increased over time from the first adalimumab dose to
week 52 of treatment and was sustained up to week 196
of treatment (Fig. S3).
Pharmacokinetics and immunogenicity
Serum adalimumab trough concentrations over time (from
week 52 through week 196) for patients who were ran-
domized to receive adalimumab in the lead-in study and
entered the open-label extension study are presented by
dose-escalation status (at any time) in Fig. 5a. Serum
adalimumab concentrations in patients who continued to
receive 40 mg every other week remained relatively con-
stant from week 52 (mean ± standard deviation of
8.3 ± 4.7 lg/mL) through week 196 (8.8 ± 5.3 lg/mL).
Concentrations increased in patients whose treatment was
escalated to 80 mg every other week—from
11.7 ± 8.5 lg/mL at week 52 to 20.0 ± 11.7 lg/mL at
week 196.
Sixteen of 190 patients (8.4%) were AAA positive
during the open-label extension study, 10 of whom were
AAA positive when they entered the study and 6 of whom
became AAA positive after week 52. The mean serum
concentration of adalimumab over time by AAA status and
by dose-escalation status in the open-label extension study
is shown in Fig. 5b. Serum adalimumab concentrations
were higher in AAA-negative patients than in AAA-posi-
tive patients.
Table 1 Demographics and clinical characteristics at lead-in study
enrollment of all patients in the ‘‘any ADA’’ set (N = 266)
Value
Age (years)a 42.6 (14.4)
Sex, male 175 (65.8%)
Disease duration (years)a 8.1 (7.2)
Site of ulcerative colitis
Entire large intestine 171 (64.3%)
Descending colon 92 (34.6%)
Otherb 3 (1.1%)
Mayo scorea 8.5 (1.46)
Partial Mayo scorea 6.1 (1.3)
Ulcerative colitis disease activity index scorea 8.5 (1.5)
IBDQ scorea,c 146.4 (29.6)
SF-36 scorea,d
Physical component 45.2 (7.2)
Mental component 39.4 (11.6)







IBDQ Inflammatory Bowel Disease Questionnaire
a The mean is given, with the standard deviation in parentheses
b Distal colitis and appendix or ascending colon, colon or rectal colon
or transverse colon, and rectal to sigmoid colon
c N = 262
d N = 265 (missing result for one patient)




Two hundred sixty-six Japanese patients with ulcerative
colitis received one or more doses of adalimumab in the
phase 2/3 study, representing 579.1 patient-years of expo-
sure. An overview of treatment-emergent adverse events
reported in the any ADA set is presented in Table 2.
The rates of any adverse events, possibly drug-related
adverse events, severe adverse events, and serious adverse
events were lower in the any ADA set than during the
double-blind period. Also, the rates per 100 patient-years
of infections, serious infections, opportunistic infections,
tuberculosis, and adverse events leading to discontinuation
Fig. 2 Efficacy of adalimumab
over time for patients regardless
of dose in the ‘‘any ADA’’ set
and imputing patients whose
treatment was escalated to
80 mg every other week as
nonresponders (‘‘no dose
escalation’’). Rates of
a remission per full Mayo score
(FMS), b response per FMS,
and c mucosal healing
(endoscopy subscore 1 or less)
(hybrid nonresponder




of therapy were lower in the any ADA set than during the
double-blind period.
The most frequent adverse event was worsening of
ulcerative colitis. Malignancies were reported in eight
patients, and all were judged to be unrelated to the study
drug. No hepatic or hematologic adverse event required
interruption or discontinuation of adalimumab treatment.
During treatment with adalimumab, tuberculosis was
reported in two patients. Both events were considered by
the investigator to be probably not related to the study
drug. One of these patients, a 65-year-old man in the
adalimumab 160/80 arm, died of tuberculosis on day 91
(62 days after the last dose). He had erythema larger than
10 mm but no induration on purified protein-derivative
skin test at the baseline and was also receiving prednisone
(20 mg/day) [18]. In addition, a 46-year-old man reported
mild and nonserious Mycobacterium tuberculosis infection
50 days after the first adalimumab dose. Adalimumab
therapy was discontinued on day 60 because of colon
stenosis. Two deaths (one due to pancreatic carcinoma, the
other due to tuberculosis, as described above) occurred
during the double-blind period and were reported previ-
ously [18]. Both deaths were considered to be unrelated to
the study drug. No deaths occurred during the open-label
extension study.
In patients whose adalimumab dose was increased from
40 mg every other week to 80 mg every other week, the
rates of any adverse events and of serious and opportunistic
infections remained unchanged (Table S1). Most of the
serious adverse events reported after dose escalation were
related to ulcerative colitis.
Discussion
This study has demonstrated the benefit of maintenance
treatment with adalimumab for up to 4 years in Japanese
patients with moderately to severely active ulcerative
colitis. The remission rate per PMS was 30.8% (hNRI
analysis) after 52 weeks of adalimumab treatment and
was generally consistent throughout the open-label
extension study up to week 196 (22.5%) of treatment.
Similarly, the response rate per PMS (40.2% at week 52)
was sustained through week 196 (32.5%) of adalimumab
treatment.
Fig. 4 Proportion of patients in
the ‘‘any ADA’’ set who
achieved remission per the
Inflammatory Bowel Disease
Questionnaire (IBDQ) score
(IBDQ score 170 points or
greater) over time by duration of
adalimumab (ADA) treatment
(hybrid nonresponder
imputation; N = 266)
Fig. 3 Proportion of patients who used corticosteroids at lead-in
study enrollment and who discontinued corticosteroid therapy over
time (observed analysis; N = 175). ADA adalimumab
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The importance of mucosal healing as a therapeutic goal
in ulcerative colitis (because of its association with favor-
able long-term outcomes such as long-term clinical
remission, corticosteroid-free clinical remission, and
avoidance of colectomy) has been demonstrated in several
clinical studies, and was recently confirmed by a meta-
analysis [19]. Clinically meaningful proportions of Japa-
nese patients maintained mucosal healing up to 196 weeks
of treatment (30.5%) in the present study. In addition, high
proportions of patients who used corticosteroids at the
lead-in study baseline were able to discontinue using
steroids (69.0% at week 196 of treatment) and achieve
steroid-free remission (40.5% at week 196 of treatment)
with adalimumab treatment over time.
The long-term maintenance of efficacy of adalimumab
therapy observed in Japanese patients is consistent with
reports in Western patients. In the open-label extension
study ULTRA 3, 24.7% of patients randomized to receive
adalimumab at the study baseline achieved remission per
PMS and 27.7% had mucosal healing after 4 years of
therapy. Furthermore, approximately 60% of patients using
corticosteroids at the lead-in study baseline were able to
discontinue using corticosteroids at 4 years [17].
Approximately 40–50% of patients may not initially
respond to anti-TNFa therapy, and about half of patients
lose their response over time. However, the therapeutic
value of dose escalation has been demonstrated in Western
patients from ULTRA 2 who had lost their response to
adalimumab, and these findings were confirmed in the
Fig. 5 Adalimumab trough serum concentrations over time in
patients who entered the open-label extension study a by dose-
escalation status (continuing with 40 mg every other week vs
escalation to 80 mg every other week) and b by dose-escalation
status and anti-adalimumab antibody (AAA) status. The error bars
denote standard deviation. Single asterisk median number of weeks of
increased dose was 34 (range 15–155), two asterisks median number
of weeks of increased dose was 31 (range 15–155) in AAA-negative
patients and 79 (range 20–114) in AAA-positive patients, eow every
other week
Table 2 Treatment-emergent adverse events during adalimumab
treatment for patients in the ‘‘any ADA’’ set (N = 266; 579.1 patient-
years)
Adverse event Eventsb
Any adverse event 2,499 (431.5)
Any adverse event at least possibly drug related 294 (50.8)
Severe adverse event 20 (3.5)
Serious adverse event 129 (22.3)




Serious infection 23 (4.0)
Opportunistic infectiona 10 (1.7)
Tuberculosis 2 (0.3)
Ulcerative colitis worsening or flare 68 (11.7)
Injection site reaction 38 (6.6)
Hematologic adverse event 16 (2.8)
Allergic reaction 12 (2.1)
Hepatic adverse event 10 (1.7)
Any malignancy 8 (1.4)
Lymphoma 0
Nonmelanoma skin cancer 0




Cerebrovascular accident 1 (0.2)
Interstitial lung disease 1 (0.2)
Erythema multiforme 1 (0.2)




a Excluding oral candidiasis and tuberculosis
b The number of events per 100 patient-years is given in parentheses
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present study in Japanese patients [20]. Allowing adali-
mumab dose escalation to 80 mg every other week in
patients who experienced an inadequate response or dis-
ease flare resulted in higher rates of clinical response per
PMS over time in the any ADA set than in patients who
continued to receive 40 mg every other week.
Ulcerative colitis is associated with diminished quality
of life, and a significant proportion of patients, particularly
those with more severe symptoms, are unable to lead
normal lives [21]. The current study has shown that the
quality-of-life improvements observed in the original study
were clinically meaningful and could be maintained for up
to 4 years with long-term adalimumab administration.
No new safety signals were observed during the open-
label extension study, and dose escalation to 80 mg every
other week did not alter the safety profile of adalimumab.
The safety of up to 4 years of treatment with adalimumab
is consistent with the safety outcomes of the double-blind
study [18] and other studies of adalimumab in ulcerative
colitis [17] and other indications [22–24]. During the
extension study, the exposure-adjusted incidence rates of
adverse events, including serious adverse events, serious
and opportunistic infections, malignancies, and hepatic and
hematologic events, declined or remained similar to those
in the 52-week double-blind period, thus providing evi-
dence that there is no cumulative safety risk over time
associated with long-term adalimumab therapy.
In AAA-negative patients who received adalimumab
40 mg every other week throughout their treatment, the
mean serum adalimumab concentrations were constant for
up to 4 years and were within the range of concentrations
reported in Japanese Crohn’s disease patients who received
the same dose. Consistently higher adalimumab concen-
trations were reported over time in patients with ulcerative
colitis whose dose was escalated to 80 mg every other
week than in dose escalators from the trial in Japanese
patients with Crohn’s disease. In contrast, no noticeable
difference in serum adalimumab concentration was iden-
tified in patients from both trials who continued to receive
adalimumab 40 mg every other week [24]. An increase in
adalimumab concentration after dose escalation is consis-
tent with the higher response rates seen in the any ADA set
than in the no-dose-escalation set reported above.
Immunogenicity (one of more AAA-positive sample)
developed in a small percentage of patients (8.4%) during
the study, in line with data on development of immuno-
genicity in Japanese patients treated with adalimumab for
Crohn’s disease (6.1%) [24].
The limitations of this study include its relatively small
sample size, restriction to a Japanese population, and the
open-label design of the extension period of the study. All
patients who were recruited into the phase 2/3 study before
the open-label extension study reported here were anti-
TNFa naı¨ve; hence this study cannot provide insights into
the relative efficacy of adalimumab in anti-TNFa-naı¨ve
versus anti-TNFa-experienced patients. It would also be of
interest to investigate how the results in this clinical trial
setting compare with those in real-life clinical practice in
Japan. A recent registry-based Spanish study reported a
trend for higher 1-year response and remission rates with
adalimumab therapy in anti-TNFa-naı¨ve patients with
ulcerative colitis compared with those previously treated
with an anti-TNFa agent in routine clinical practice [25].
As with any long-term clinical study, there was loss of
patient data over time due to early termination (e.g.,
because of lack of efficacy or adverse events). Another
reason for discontinuation in our study is that adalimumab
became commercially available during the study after its
approval for the treatment of ulcerative colitis. Therefore,
hNRI analysis was applied to binary efficacy end points,
using stringent nonresponder imputation methodology until
the latest possible time of observation of each enrolled
patient and analysis of observed data thereafter. However,
there are also several methodological strengths. The fol-
low-up duration was extended to 4 years, the study was
conducted according to strict quality standards compliant
with good clinical practice, prospective data (including
endoscopic and pharmacokinetic data) were systematically
collected, and analyses of end points were prespecified.
In conclusion, this study has demonstrated that the
beneficial effect of adalimumab for the treatment of mod-
erately to severely active ulcerative colitis in Japanese
patients is maintained through 4 years without the intro-
duction of new safety signals.
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